NEUP (32) AEON (48) RADX (61) JAGX (31) ⌘ Pro Terminal →

Marker Therapeutics Inc. (MRKR) — RQD Stock Rating Cockpit

$1.01 +1.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.01

Marker Therapeutics Inc. (MRKR) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $16.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.01 (-0.01%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MRKR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY MRKR SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (31% of score)

FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 44.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.97+7.2% Next Q

Q2 (-2Q)

Grade D$1.04-7.7% Next Q

Q3 (-1Q)

Grade D$0.96+5.2% Next Q

Current

Grade D$1.01-5.6% Hist 90D α

Trajectory: D (40) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MRKR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MRKR currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($1.06) forces dealer call-delta covering toward $2.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRKR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MRKR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

44.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE10% OF RANGE

L: $1$1.01H: $2

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on MRKR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (52)

16/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like MRKR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MRKR)

✓Walkthrough of MRKR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MRKR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.82%▼ DESCENDING CHANNEL

2026-10-30O $1.03H $1.04L $0.96C $1.01VOL 67.6K

RES: $1.44SUP: $0.83SMA50: $1.15SMA200: $1.37

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MRKR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MRKR Butterfly Map → + Track MRKR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MRKR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MRKR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MRKR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRKR)

Health Care Rank #394 of 1016 ⚔️ NEUP vs MRKR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MRKR vs. NEUP, AEON, RADX, JAGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Marker Therapeutics Inc. (MRKR) ranks #394 by composite RQD confidence (48/100, grade D) and #846 by equity capitalization ($16.8M). Within this direct 5-issuer industry benchmark cohort, MRKR leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with MRKR at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MRKR ACTIVE Marker Therapeutics Inc.	D	48/100	—	—	-35.0%	+1.00%	$16.8M	Benchmark Subject
NEUP Neuphoria Therapeutics Inc.	E	32/100	—	—	-11.8%	-8.93%	$16.6M	/neup-vs-mrkr →
AEON AEON Biopharma Inc. (Class A)	D	48/100	—	—	-35.0%	+11.36%	$17.4M	/aeon-vs-mrkr →
RADX Radiopharm Theranostics Limited	C-	61/100	—	—	—	+17.52%	$16.1M	/radx-vs-mrkr →
JAGX Jaguar Health Inc.	E	31/100	—	67.2%	-35.0%	-2.86%	$15.9M	/jagx-vs-mrkr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001094038

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Marker Therapeutics Inc. (MRKR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.2M, operating cash flow of -$12.0M, and free cash flow of -$12.0M (-10.1% YoY). On the balance sheet, MRKR closed FY2025 with $19.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$12.2M	-$12.0M	-$12.0M	$19.1M	—
FY2024 (FY)	2024-12-31	$0	-$10.7M	-$10.9M	-$10.9M	$22.0M	—
FY2023 (FY)	2023-12-31	$0	-$8.2M	-$16.4M	-$16.4M	—	—

3. MRKR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Marker Therapeutics Inc. (NASDAQ: MRKR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $1.01 (+1.00% 1D, market cap $16.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MRKR ranks #394 in composite RQD confidence.

How does MRKR compare to NEUP and AEON in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRKR carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NEUP (Neuphoria Therapeutics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -11.8%, cap $16.6M) and AEON (AEON Biopharma Inc. (Class A)) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $17.4M). Among the 5-stock peer group, MRKR leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MRKR?

Per MRKR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001094038), Marker Therapeutics Inc. generated $0 in revenue, -$12.2M in net income, and -$12.0M in free cash flow against $19.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MRKR trading relative to its 50-day, 200-day, and 52-week technical levels?

MRKR last traded at $1.01 (+1.00% on volume of 72,941 shares), positioning the stock -12.17% below its 50-day simple moving average ($1.15) and -26.28% below its 200-day simple moving average ($1.37). Across its 52-week range of $0.84 to $2.46, MRKR sits at the 10.5% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).

MRKR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MRKR stock right now?

Marker Therapeutics Inc. (MRKR) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is MRKR's 12-month price target and RQD AI Jury consensus?

MRKR's 12-month base price target is $0.96 (range $0.75 to $2.58), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MRKR RQD Cockpit MRKR 12M Forecast MRKR Earnings & Move MRKR Dividends & DRIP MRKR Insiders & 13F MRKR Whale Options MRKR Profit Sankey MRKR News & Why